Bordetella bronchiseptica: Microbiology, Pathogenesis, Diagnostics, and Control in Veterinary Medicine

Introduction and Taxonomic Classification

Bordetella bronchiseptica is a Gram-negative, aerobic, coccobacillus belonging to the genus Bordetella within the family Alcaligenaceae [1, 2]. The organism is a primary or secondary respiratory pathogen of a wide range of mammalian hosts, including dogs, cats, pigs, rodents, lagomorphs, and non‑human primates [3, 4, 5, 6]. Phylogenetically, B. bronchiseptica clusters closely with Bordetella pertussis and Bordetella parapertussis, but it retains a broader host tropism and a more versatile genomic repertoire [4, 7]. The species is a common etiological agent of canine infectious respiratory disease complex (CIRDC), often referred to as kennel cough Bordetella bronchiseptica in Dogs and Cats: Kennel Cough Pathogenesis, Diagnosis, and Control. In swine, it is a key contributor to progressive and non‑progressive atrophic rhinitis Bordetella bronchiseptica and Atrophic Rhinitis in Pigs: Turbinate Atrophy and Diagnosis. The bacterium also causes upper respiratory infections in cats, often in concert with feline herpesvirus‑1 and calicivirus Feline Upper Respiratory Infections (Feline Herpesvirus, Calicivirus, and Bordetella): Etiology, Clinical Signs, Zoonotic Potential, and Therapeutics.

Microbiology and Virulence Determinants

B. bronchiseptica expresses a suite of virulence factors that enable colonization, immune evasion, and tissue damage. Key adhesins include filamentous hemagglutinin, pertactin, and fimbriae; the latter are encoded by the fim locus, which exhibits substantial diversity among isolates [8]. The fimX locus, in particular, shows variable allelic content that may influence host specificity [8]. A recently described colonization glycan, termed b‑Cool (Bordetellae colonization oligosaccharide), is critical for nasal colonization and resistance to mucociliary clearance [2].

The bacterium produces several toxins. Dermonecrotic toxin (DNT) is a heat‑labile protein that causes turbinate atrophy in pigs and contributes to nasal pathology in other species [9]. Adenylate cyclase toxin (CyaA) is a bifunctional enzyme that elevates intracellular cyclic AMP, impairing phagocyte function; its acylation and secretion patterns differ among Bordetella species and may correlate with virulence [10]. The type III secretion system (T3SS) injects effector proteins into host cells; the tip filament of the injectisome undergoes dynamic assembly regulated by environmental cues [11]. Cyclic di‑GMP (c‑di‑GMP) signaling modulates biofilm formation and motility, with architectural and regulatory functions that are conserved across classical Bordetella species [1]. Biofilm regulation is further influenced by albumin and calcium, which act as environmental signals [12].

Clinical Syndromes and Host Range

Dogs

In dogs, B. bronchiseptica is a predominant bacterial cause of CIRDC. Clinical features include paroxysmal coughing, mucopurulent nasal discharge, and, in severe cases, bronchopneumonia [13]. Risk factors for lower respiratory tract involvement include concurrent viral infection, immunosuppression, and shelter housing [13]. Acute bronchopneumonia with bacteremia, although rare, has been documented in immunocompromised dogs [14]. Bacteremia is more commonly reported in human cases, but analogous presentations occur in dogs with severe mucosal damage.

Cats

Feline infection is often subclinical or manifests as mild conjunctivitis and sneezing. In multi‑cat environments, B. bronchiseptica can cause overt respiratory disease, particularly in kittens [15]. The organism is frequently detected in cats co‑infected with feline herpesvirus‑1 or calicivirus Feline Upper Respiratory Infections: Etiology, Transmission, Clinical Management, and Zoonotic Potential.

Pigs

B. bronchiseptica is a primary agent of non‑progressive atrophic rhinitis and predisposes pigs to colonization by toxigenic Pasteurella multocida, which causes progressive atrophic rhinitis [16, 17]. A vertical transmission model has been developed, demonstrating that sows can transmit the bacterium to piglets, contributing to early‑life colonization [16].

Wildlife

Eastern gray squirrels (Sciurus carolinensis) harbor B. bronchiseptica at variable prevalence, with no clear association with clinical disease [3]. In koalas (Phascolarctos cinereus), the bacterium is detected in both healthy and diseased animals, often alongside Chlamydia spp. and gammaherpesviruses [5]. Non‑human primates (e.g., macaques) carry genetically diverse B. bronchiseptica strains, some of which are closely related to human isolates [6].

Zoonotic Potential

B. bronchiseptica can infect immunocompromised humans, causing pneumonia, chronic cough, and empyema [14, 18, 19, 20]. Genomic analyses of swine‑human interface isolates reveal evolutionary pathways that facilitate host switching, emphasizing the zoonotic risk posed by livestock reservoirs [4]. However, human‑to‑human transmission is considered uncommon.

Diagnostic Approaches

Accurate diagnosis relies on a combination of culture, molecular methods, and serology. The table below summarizes the principal diagnostic techniques.

Molecular diagnostics are increasingly preferred because of speed and sensitivity. Real‑time PCR using the IS481 insertion sequence (shared with B. pertussis) can cause confusion; species‑specific targets (e.g., recA, pixP) improve discrimination [25, 23]. A combined PCR and LAMP assay targeting multiple Bordetella species has been developed for use in respiratory panels [23]. Point‑of‑care molecular platforms for feline upper respiratory pathogens, including B. bronchiseptica, are available for veterinary clinics Point‑of‑Care Molecular Diagnostics for Feline Upper Respiratory Pathogens: FHV‑1, FCV, and Bordetella.

Serological detection by ELISA has been correlated with infection in dogs, and serum amyloid A levels may serve as an adjunct marker for active disease [24]. Multiplex bead‑based assays enable simultaneous detection of antibodies against multiple feline respiratory pathogens Development of a Multiplex Bead‑Based Serological Assay for Detection of Antibodies against Feline Respiratory Pathogens (FHV‑1, FCV, and Bordetella bronchiseptica).

Diagnostic Decision Tree

The following Mermaid diagram illustrates a diagnostic workflow for a dog or cat presenting with respiratory signs.

flowchart TD
    A[Respiratory signs: cough, nasal discharge, sneezing], > B{Clinical severity?}
    B, >|Mild| C[Non‑invasive swab: nasal or oropharyngeal]
    B, >|Severe or chronic| D[BAL or transtracheal wash]
    C, > E[Real‑time PCR for B. bronchiseptica + viral panel]
    D, > E
    E, >|Positive for B. bronchiseptica| F{Co‑pathogen detected?}
    E, >|Negative| G[Consider culture, serology, or alternative diagnosis]
    F, >|Yes| H[Treat primary pathogen + manage B. bronchiseptica]
    F, >|No| I[Antimicrobial therapy guided by susceptibility or business intelligence tools]
    I, > J[Monitor clinical response]
    J, >|No improvement| K[Repeat PCR ± culture from BAL; consider resistance testing]

Vaccination Strategies

Multiple vaccine formulations are available for dogs and cats, including live attenuated oral, intranasal, and injectable inactivated products. The table below summarizes key vaccine studies.

Oral and intranasal vaccines are preferred in dogs for rapid mucosal immunity; injectable formulations are used in cats and as alternatives in dogs [26, 15, 29]. A novel nanocage‑based vaccine demonstrates cross‑species protection, suggesting potential for future broad‑spectrum applications [31].

Antimicrobial Resistance and Treatment

Acquired antimicrobial resistance genes in B. bronchiseptica have been characterized globally. Genomic analyses reveal that resistance to macrolides, tetracyclines, and sulfonamides is common in porcine and canine isolates, while fluoroquinolone resistance remains less frequent [7]. Business intelligence tools that integrate local surveillance data can guide empirical antimicrobial choices [32]. Doxycycline is often the first‑line agent, but susceptibility testing is advised when feasible.

Phage Therapy

Bacteriophages represent a promising alternative to antibiotics for treating B. bronchiseptica infections. A phage with dual host specificity for canine and porcine isolates has been isolated and shown to disrupt biofilms [33]. A broad‑spectrum lytic phage capable of lysing multiple Bordetella species has also been characterized, raising the possibility of pan‑Bordetella phage therapy [34]. Phage therapy is not yet approved for veterinary use but is under active investigation.

Pathogen Evolution and Genomics

Comparative genomics reveals substantial diversity among B. bronchiseptica isolates from primates, with distinct lineages correlating with geographic origin and host species [6]. The fimX locus is hypervariable, likely driven by host immune selection [8]. Genetic events at the swine‑human interface have been traced, showing that zoonotic strains evolve by acquisition of pertussis‑toxin‑like loci and loss of host‑restriction factors [4]. c‑di‑GMP signaling networks show nuanced differences across classical Bordetella species, affecting virulence gene expression [1].

Frequently Asked Questions

What is Bordetella bronchiseptica?

Bordetella bronchiseptica is a Gram‑negative coccobacillus that causes respiratory infections in a wide range of mammals, including dogs, cats, pigs, rodents, and non‑human primates [1, 2]. It is a primary component of the canine infectious respiratory disease complex and contributes to atrophic rhinitis in pigs.

How is Bordetella bronchiseptica transmitted?

Transmission occurs via aerosolized respiratory droplets, direct contact with contaminated fomites, and, in swine, vertically from sow to piglet [16]. Crowded housing conditions, such as shelters and kennels, facilitate rapid spread.

What are the clinical signs in dogs?

Dogs typically develop a harsh, paroxysmal cough, nasal discharge, and occasional fever; in severe cases, bronchopneumonia and bacteremia can occur [13, 14].

What are the clinical signs in cats?

Cats often exhibit mild sneezing, conjunctivitis, and serous nasal discharge, but kittens and immunocompromised adults may develop pneumonia [15].

How is Bordetella bronchiseptica diagnosed?

Diagnosis is confirmed by real‑time PCR performed on nasal swabs or bronchoalveolar lavage fluid; culture and serology are adjunct methods [21, 23, 24]. Multiplex panels can distinguish B. bronchiseptica from other Bordetella species.

What vaccines are available?

Oral live attenuated, intranasal, and injectable inactivated vaccines are licensed for dogs and cats [26, 15, 29]. Experimental subunit, nanocage, and Th17‑inducing vaccines have shown promise in murine models [28, 31, 30].

Is Bordetella bronchiseptica zoonotic?

Yes, immunocompromised humans can acquire infection from animals, particularly through contact with pigs or dogs [14, 4, 18, 19, 20]. Person‑to‑person spread is rare.

How is infection treated?

Doxycycline is a common first‑line antimicrobial, but susceptibility testing is recommended due to increasing antimicrobial resistance [7, 32]. Phage therapy is being explored as an alternative [33, 34].

References

[1] Vondrova D, Mugni SL, Blumenstein J, et al. Architecture and regulatory functions of c‑di‑GMP signaling in classical Bordetella species. FEMS Microbiol Rev. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41452322/

[2] Su Y, Callender M, Woolsey D, et al. Bordetellae colonization oligosaccharide (b‑Cool), a glycan crucial for nasal colonization. Sci Adv. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40901963/

[3] Laird G, Calinger‑Yoak A, Zhang Q. Survey of Bordetella bronchiseptica in Eastern Gray Squirrels (Sciurus carolinensis). Ecohealth. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41989687/

[4] Liu J, Zheng X, Jia C, et al. Zoonotic Bordetella bronchiseptica infection at the swine‑human interface: unveiling the evolutionary path from an animal to a human pathogen. Emerg Microbes Infect. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41729089/

[5] Pollak NM, Phillips S, Kasimov V, et al. Chlamydia spp., Bordetella bronchiseptica, and Phascolarctid Gammaherpesvirus 1 and 2 Infections in Koalas (Phascolarctos cinereus) in South East Queensland, Australia: Detection in Healthy Individuals and Those with Signs of Respiratory or Other Disease. J Wildl Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41638597/

[6] Nicholson TL, Shore SM, Wang Y, et al. Genetic diversity of Bordetella bronchiseptica isolates obtained from primates. Front Microbiol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40641881/

[7] Tang B, Hu X, Song Y, et al. Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis. J Antimicrob Chemother. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41324307/

[8] Nicholson TL, Shore SM. Comparative analysis of the diversity within the B. bronchiseptica fimX locus. PLoS One. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41770752/

[9] Schaaf D, Dresen M, Weldearegay YB, et al. Mono‑ and co‑infections of primary porcine respiratory cells with Bordetella bronchiseptica and Streptococcus suis are not affected by the dermonecrotic toxin. Infect Immun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41817187/

[10] Wolber AR, McKay LS, Mote KB, et al. Nuanced differences in adenylate cyclase toxin production, acylation, and secretion may contribute to the evolution of virulence in Bordetella species. mBio. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40387377/

[11] Malcova I, Zmuda M, Valecka J, et al. Assembly and dynamic regulation of the tip filament of the Bordetella type III secretion system injectisome. mBio. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40980893/

[12] Mugni SL, Ambrosis N, O Toole GA, et al. Interplay of virulence factors and signaling molecules: albumin and calcium‑mediated biofilm regulation in Bordetella bronchiseptica. J Bacteriol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40135913/

[13] Marshall GR, Makielski KM, Rendahl AK, et al. Clinical features, risk factors, and outcomes of Bordetella bronchiseptica respiratory infections in dogs diagnosed at a tertiary care institution. J Vet Intern Med. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42059462/

[14] Takahashi Y, Isshiki R, Kimoto K, et al. Acute bronchopneumonia with Bordetella bronchiseptica bacteremia in an immunocompromised patient with bronchiectasis: A case report and review of the literature. J Infect Chemother. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41903648/

[15] Li Y, Dong X, Yang A, et al. Development and efficacy evaluation of an inactivated Bordetella bronchiseptica vaccine in cats. Vaccine. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42217448/

[16] Hau SJ, Buckley AC, Arruda B, et al. Development of vertical transmission model for Bordetella bronchiseptica in pigs. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41740208/

[17] Lichterfeld H, Trittmacher S, Gerdes K, et al. Correction: Lichterfeld et al. Porcine Nose Atrophy Assessed by Automatic Imaging and Detection of Bordetella bronchiseptica and Other Respiratory Pathogens in Lung and Nose. Animals 2024, 14, 3113. Animals (Basel). 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40805115/

[18] Banerjee D, Ayaz E, Hudson A, et al. Chronic Productive Cough in an Immunosuppressed Patient due to Biologics: A Rare Case of Bordetella bronchiseptica Pulmonary Infection. Respirol Case Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41503239/

[19] Saleem Siddiqui A. Bordetella bronchiseptica Pneumonia in an Immunocompetent Young Man. Arch Bronconeumol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40783308/

[20] Wray S, Tabliago NRA, Lueking R. B. Bronchiseptica empyema necessitans, a case report. BMC Pulm Med. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40346537/

[21] Atencia S, Mateu N, Rodríguez‑Cobos A, et al. Real‑time PCR versus culture of bronchoalveolar lavage fluid for detecting Bordetella bronchiseptica in dogs with persistent lower respiratory signs: a retrospective study of 23 cases. Vet Res Commun. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40663178/

[22] Abbasi Bahonar A, Hadian M, Ownagh A, et al. Genomic detection and phylogenetic analysis of Bordetella bronchiseptica in dogs blood samples by PCR method in West Azerbaijan Province, Iran. Braz J Microbiol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41364275/

[23] Koryukov MA, Oscorbin IP, Gordukova MA, et al. Novel multitarget LAMP and PCR assays for the detection of Bordetella species. Methods. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40216281/

[24] Akar K, Sanioğlu Gölen G, Ekin İH. Investigation of the Correlation Between ELISA and Serum Amyloid A in the Diagnosis of Bordetella bronchiseptica in Dogs. Vet Med Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40214008/

[25] Zarbock CM, Evbuomwan EM, Shenep M, et al. Molecular methods to diagnose pertussis: a case of confusion with Bordetella bronchiseptica. ASM Case Rep. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41244292/

[26] Wappel S, Velineni S, King V, et al. Oral administration of a live‑attenuated Bordetella bronchiseptica vaccine (Vanguard B Oral) induces protective immunity against challenge 7 days after vaccination in dogs. Am J Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42379217/

[27] Wiechert‑Brown SA, Classe HM, Dant JC, et al. One year duration of immunity of a combination Bordetella bronchiseptica – canine parainfluenza oral vaccine in dogs. Front Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41164231/

[28] Aubrey AR, Patel KK, Hall JM, et al. A BcfA‑containing intranasal vaccine generated T(H)17 immunity and reduced B. bronchiseptica colonization and disease in mice. NPJ Vaccines. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42103775/

[29] Bruton B, Wouters PAWM, Tarpey I, et al. A Novel Vitamin E Adjuvanted Injectable Bordetella bronchiseptica Vaccine Is Safe and Efficacious in Dogs. Vaccines (Basel). 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42042820/

[30] Jang JY, Park BJ, Song H, et al. Safety and efficacy of a Bordetella bronchiseptica outer membrane proteins (OMPs) subunit vaccine in a murine model. J Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40461428/

[31] He W, Wang L, Zhang X, et al. Programmable trivalent nanocage vaccine confers durable cross‑species protection against Bordetella bronchiseptica infection. J Nanobiotechnology. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41736107/

[32] Rodríguez‑Villodres Á, Hoffmann‑Álvarez MV, Camacho‑Martínez P, et al. Usefulness of business intelligence to guide antimicrobial treatment decision in infections by infrequent microorganism such as Bordetella bronchiseptica. Rev Esp Quimioter. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40080405/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[33] Li C, Tan L, Ma Y, et al. A bacteriophage with dual host specificity for canine and porcine Bordetella bronchiseptica: Characterization and biofilm disruption potential. Virology. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41108833/

[34] Huang X, Hou Y, Zhao M, et al. Identification of a broad‑spectrum lytic Bordetella phage and assessments of its potential for combating Bordetella infections. Virology. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40306109/

[35] Kadhim HM, Al‑Galebi AAS, Al‑Hassani MKA, et al. Molecular and serological incidences of Bordetella bronchiseptica in pet dogs with urinary infections. Open Vet J. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40276197/